Workflow
biotech
icon
Search documents
Why Investors Were Avoiding GeneDx Holdings Stock This Week
The Motley Fool· 2025-05-02 20:23
With a nearly 39% stock price decline this week, according to data compiled by S&P Global Market Intelligence, GeneDx Holdings (WGS 7.80%) was deep in the doghouse with investors. They traded out of the stock following the company's latest earnings release and a subsequent round of analyst price target cuts.A victim of high expectationsWhat's interesting about GeneDx's tumble is that its first-quarter performance was, on the surface, rather good. The figures released Wednesday revealed the DNA testing compa ...
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
Seeking Alpha· 2025-05-01 20:31
Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author previously wrote about Alkermes, focusing on potential narcolepsy data that could influence the company's future [2] - The article emphasizes that the author has no financial positions in the companies mentioned, ensuring an unbiased perspective [3]
Twist Bioscience Q2 Earnings Preview: Innovative Products, Not Enough Buyers
Seeking Alpha· 2025-05-01 16:05
Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [2]
Ligand to Participate in May Investor Conferences
Globenewswire· 2025-05-01 11:00
Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Upcoming Investor Conferences - Ligand management will participate in the H.C. Wainwright Royalty Company Conference on May 13, 2025, at 3:30 p.m. ET, including a fireside chat and one-on-one meetings [4] - Management will also take part in the RBC Capital Markets Global Healthcare Conference on May 20, 2025, at 2:05 p.m. ET, featuring a fireside chat and one-on-one meetings [4] - Additionally, Ligand will engage in one-on-one meetings at the Craig-Hallum Institutional Investor Conference on May 28, 2025 [4] Technology Platforms - Ligand operates two infrastructure-light royalty-generating technology platforms: Captisol® and NITRICIL™ [2] - The Captisol® platform is designed to optimize the solubility and stability of drugs through a chemically modified cyclodextrin structure [2] - The NITRICIL™ platform allows for tunable dosing, enabling adjustable drug release profiles for proprietary formulations targeting a broad range of indications [2] Investor Relations - The company utilizes its investor relations website and social media to disclose material non-public information and comply with disclosure obligations under Regulation FD [3] - Investors are encouraged to monitor the company's website and social media accounts for updates, press releases, SEC filings, and public conference calls [3]
Rezolute: RZ402 Could Be A Surprise Candidate In The Making
Seeking Alpha· 2025-05-01 07:57
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
Prnewswire· 2025-04-28 20:01
Core Viewpoint - Amgen is set to report its first quarter 2025 financial results on May 1, 2025, followed by a conference call with senior management [1] Group 1: Financial Reporting - Amgen will announce its Q1 2025 financial results after the close of U.S. financial markets on May 1, 2025 [1] - A conference call will take place at 4:30 p.m. ET, featuring CEO Robert A. Bradway and other senior management members [1] Group 2: Conference Call Details - The conference call will be broadcast live over the internet, accessible to media, investors, and the general public [2] - The webcast will be archived for at least 90 days for replay [3] Group 3: Company Overview - Amgen is a leader in biotechnology, focusing on innovative medicines for serious diseases, with over 40 years of industry experience [4] - The company has a diverse pipeline targeting cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases [4] Group 4: Recognition and Index Inclusion - In 2024, Amgen was recognized as one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes [5] - Amgen is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its market capitalization and innovation [5]
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Seeking Alpha· 2025-04-28 19:26
Core Insights - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1 - The service offers a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price of $399, which represents a 33.50% discount compared to the monthly rate [1]. - The author emphasizes that the analysis is independent and not influenced by any business relationships with the companies mentioned [3].
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101
Seeking Alpha· 2025-04-25 22:16
Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author previously wrote about Galapagos NV and its potential impact on the biotech landscape with its product GLPG5101 [2] - The article emphasizes the importance of thorough research and analysis in the biotech sector for investment decisions [2]
Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025
Seeking Alpha· 2025-04-22 22:05
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech
Seeking Alpha· 2025-04-22 13:15
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...